Results 131 to 140 of about 25,762 (279)

ATYPICAL HEMOLYTIC-UREMIC SYNDROME IN THE FEMALE PATIENT WITH CONCURRENT MENOMETRORRHAGIA (clinical case)

open access: yesВестник анестезиологии и реаниматологии, 2018
The article describes the follow-up over the development of atypical hemolytic-uremic syndrome in the female patient suffering menometrorrhagia which manifested with concurrent metrorrhagia and was accompanied with acute renal failure.
A. V. Pyregov   +3 more
doaj   +1 more source

Typical and Atypical Hemolytic Uremic Syndrome

open access: yesKidney and Blood Pressure Research, 1996
The hemolytic uremic syndrome is the most frequent cause of acute renal failure in childhood. In the vast majority of patients, the syndrome of acute hemolysis, thrombopenia and renal dysfunction is preceded by an episode of diarrhea with or without bloody stools.
openaire   +2 more sources

Current treatment of atypical hemolytic uremic syndrome

open access: yesIntractable & Rare Diseases Research, 2014
Tremendous advances have been made in understanding the pathogenesis of atypical Hemolytic Uremic Syndrome (aHUS), an extremely rare disease. Insights into the molecular biology of aHUS resulted in rapid advances in treatment with eculizumab (Soliris(®), Alexion Pharmaceuticals Inc.).
Bernard S, Kaplan   +3 more
openaire   +3 more sources

Serological and genetic complement alterations in infection-induced and complement-mediated hemolytic uremic syndrome [PDF]

open access: yes, 2016
Background: The role of complement in the atypical form of hemolytic uremic syndrome (aHUS) has been investigated extensively in recent years. As the HUS-associated bacteria Shiga-toxin-producing Escherichia coli (STEC) can evade the complement system ...
Bakker, J.A. (Jaap)   +14 more
core   +7 more sources

Outcomes in patients with atypical hemolytic uremic syndrome treated with eculizumab in a long-term observational study

open access: yesBMC Nephrology, 2019
BackgroundThere are limited long-term outcome data in eculizumab-treated patients with atypical hemolytic uremic syndrome (aHUS). We report final results from the largest prospective, observational, multicenter study of patients with aHUS treated with ...
J. Menne   +11 more
semanticscholar   +1 more source

FHR-1 binds to C-reactive protein and enhances rather than inhibits complement activation [PDF]

open access: yes, 2017
Factor H (FH)-related protein 1 (FHR-1) is one of the five human factor H-related proteins, which share sequence and structural homology with the alternative pathway complement inhibitor FH.
Bánlaki, Zsófia   +7 more
core   +1 more source

An adult case of atypical hemolytic uremic syndrome presented with posterior reversible encephalopathy syndrome: Successful response to late-onset eculizumab treatment

open access: yesHematology Reports, 2018
Atypical hemolytic uremic syndrome is a rare and progressive disease caused by uncontrolled alternative complement activation. Dysregulatıon of the complement activation results in thrombotic microangiopathy and multiorgan damage.
Serife Solmaz Medeni   +7 more
doaj   +1 more source

Home - About - Disclaimer - Privacy